Anixa is focused on harnessing the bodyâs immune system in the fight against cancer. Anixaâs therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease. Anixaâs diagnostics portfolio includes the CchekTM liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the bodyâs immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization. Source
No articles found.
CoverUS is a privacy-by-design based mHealth platform helping to close financial g...
CoverUS is a privacy-by-design based mHealth pl...
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing nov...
Idera Pharmaceuticals is a clinical-stage bioph...
We are a leading science and technology company that delivers life-transforming me...
We are a leading science and technology company...
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company with ...
Co-Diagnostics, Inc., a Utah corporation, is a ...
Join the National Investor Network and get the latest information with your interests in mind.